tiprankstipranks
GlaxoSmithKline Pharmaceuticals Limited (IN:GLAXO)
:GLAXO
India Market
GLAXO
GlaxoSmithKline Pharmaceuticals Limited
RESEARCH TOOLSreports

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) Financial Statements

Compare
1 Followers

GlaxoSmithKline Pharmaceuticals Limited Financial Overview

GlaxoSmithKline Pharmaceuticals Limited's market cap is currently ₹419.20B. The company's EPS TTM is ₹50.717; its P/E ratio is 48.79; and it has a dividend yield of 1.29%. GlaxoSmithKline Pharmaceuticals Limited is scheduled to report earnings on February 10, 2025, and the estimated EPS forecast is ₹―. See an overview of income statement, balance sheet, and cash flow financials.
Mar 24Mar 23Mar 22Mar 21Mar 20
Income Statement
Total Revenue₹ 34.54B₹ 32.52B₹ 32.78B₹ 31.99B₹ 32.24B
Gross Profit₹ 20.34B₹ 19.67B₹ 18.28B₹ 18.04B₹ 18.27B
Operating Income₹ 13.60B₹ 8.39B₹ 7.69B₹ 7.61B₹ 5.43B
EBITDA₹ 8.87B₹ 9.03B₹ 8.49B₹ 5.36B₹ 3.92B
Net Income₹ 5.90B₹ 6.11B₹ 3.81B₹ 3.58B₹ 932.05M
Balance Sheet
Cash & Short-Term Investments₹ 18.57B₹ 18.12B₹ 29.03B₹ 11.37B₹ 10.62B
Total Assets₹ 35.57B₹ 33.27B₹ 46.33B₹ 31.13B₹ 31.36B
Total Debt₹ 186.65M₹ 155.40M₹ 200.76M₹ 346.27M₹ 418.40M
Net Debt₹ -455.06M₹ -194.00M₹ -2.66B₹ -3.71B₹ -629.72M
Total Liabilities₹ 17.79B₹ 15.85B₹ 19.70B₹ 16.14B₹ 13.15B
Stockholders' Equity₹ 17.78B₹ 17.41B₹ 26.63B₹ 14.99B₹ 18.21B
Cash Flow
Free Cash Flow₹ 5.51B₹ 4.40B₹ 7.76B₹ 5.34B₹ 3.35B
Operating Cash Flow₹ 5.82B₹ 4.84B₹ 8.11B₹ 5.78B₹ 4.90B
Investing Cash Flow₹ -847.21M₹ 8.08B₹ -4.06B₹ 4.19B₹ -568.43M
Financing Cash Flow₹ -5.61B₹ -15.43B₹ -5.24B₹ -6.96B₹ -4.28B
Currency in INR

GlaxoSmithKline Pharmaceuticals Limited Earnings and Revenue History

GlaxoSmithKline Pharmaceuticals Limited Debt to Assets

GlaxoSmithKline Pharmaceuticals Limited Cash Flow

GlaxoSmithKline Pharmaceuticals Limited Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis